Quote | Super Quote
IPO   |   IPO News   |   Listed IPO Information   |   Hot Listed IPO
Stock Code   IPO News IPO Timetable
IPO Detail
09877 健世科技-B
Listing Date2022/10/10
Listing Price27.800
Subscription Result
  • Subscription Rate
  • Guarantee One Lot Size
    2 lot
  • One Lot Success Rate

Jenscare Scientific Co. is a China-based medical device company dedicated to the development of interventional products for the treatment of structural heart diseases. It has developed a series of treatment solutions targeting different types of structural heart diseases, including tricuspid valve diseases, aortic valve diseases, mitral valve diseases and heart failure.

LuX-Valve, its Core Product and its proprietary first-generation transcatheter tricuspid valve replacement (“TTVR”) system, is designed for patients with both severe tricuspid regurgitation and high surgical risk. It is expected to submit the trial results for NMPA approval in the fourth quarter of 2022 and obtain the NMPA approval for the commercialization of LuX-Valve in the second half of 2023.

Ken-Valve, its another Core Product, is designed for the treatment of severe aortic regurgitation (or combined with aortic stenosis). It is expected to obtain the NMPA approval for the commercialization of Ken-Valve in the first half of 2024.

As at September 13, 2022, the Group product pipeline included ten product candidates. it had 143 issued patents and 160 patent applications in more than 10 countries or regions, including China, the United States, Europe, Brazil, and Canada.

MarketHong Kong (Main Board)
Business NatureHealth Care
Major Business AreaChina
Board Lot200
No. of Offer Shares8.08M H shares
No. of International Offer Shares7.27M H shares
No. of HK Offer Shares0.81M H shares
Offer Price$26.70 - $28.80
Stock Code9877
Sponsor(s)Citigroup Global Markets Asia Limited, China International Capital Corporation Hong Kong Securities Limited
Underwriter(s)China International Capital Corporation Hong Kong Securities Limited, Citigroup Global Markets Asia Limited, Huatai Financial Holdings (Hong Kong) Limited, ABCI Securities Company Limited, BOCOM International Securities Limited, Futu Securities International (Hong Kong) Limited, Tiger Brokers (HK) Global Limited, Silverbricks Securities Company Limited
Application PeriodSep 23 (Fri) - noon, Sep 29 (Thu)
Price Determination DateSep 29 (Thu)
Result Announcement DateOn or before Oct 07 (Fri)
Result Announcement DateOn or before Oct 07 (Fri)
Dealings in Shares commence onOct 10, 2022. (Mon)
Reallocation of Shares Offered
Times of HK Offer Shares Subscription15X - 50X50X - 100XOver 100X
% of total shares reallocated to HK Offer30%40%50%
Sales Statistics (HKD)
Offer Price$26.70 - $28.80
Capitalization11.14B - 12.01B
NAV / share ($)$3.91 - $3.95 (Unaudited pro forma adj NAV / share)
Use Of Proceeds
Assuming the offer price being at HKD 27.75, the net proceeds raised would be HKD 154.40M, of which
65% : Research and development, manufacturing and commercialization of Core Products, namely, LuX-Valve and Ken-Valve
25% : Research and development, clinical trials and product registration of other product candidates in pipeline, including LuX-Valve Plus, KenFlex and mitral valve products
10% : Working capital
Related Document
Remark: The above information is referenced from the prospectus.
  All data is calculated from the non- exercise rights(if applicable).
IPO Calculator
Subscription --
Result Announcement --
Listing --
Offer Price︰--
Currency :
Listing Price :
Board Lot :
Admission Fee*
Subscribing Lot :
Subscribing Fee :

Subscribing Amount :
*Admission fees include brokerage of 1%, SFC transaction levy of 0.0027%, Stock Exchange trading fee of 0.005% and FRC transaction levy of 0.00015% (i.e. 1.0077% in total).
A Member of HKET Holdings
Customer Service Hotline:(852) 2880 7004     Customer Service Email:cs@etnet.com.hk
Copyright 2023 ET Net Limited. http://www.etnet.com.hk ET Net Limited, HKEx Information Services Limited, its Holding Companies and/or any Subsidiaries of such holding companies, and Third Party Information Providers endeavour to ensure the availability, completeness, timeliness, accuracy and reliability of the information provided but do not guarantee its availability, completeness, timeliness, accuracy or reliability and accept no liability (whether in tort or contract or otherwise) any loss or damage arising directly or indirectly from any inaccuracies, interruption, incompleteness, delay, omissions, or any decision made or action taken by you or any third party in reliance upon the information provided. The quotes, charts, commentaries and buy/sell ratings on this website should be used as references only with your own discretion. ET Net Limited is not soliciting any subscriber or site visitor to execute any trade. Any trades executed following the commentaries and buy/sell ratings on this website are taken at your own risk for your own account.